Browse News
Filter News
Found 352 articles
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033
4/12/2024
According to Nova One Advisor, the U.S. Biotechnology market size was estimated at USD 552.49 billion in 2023
-
Moderna Thursday said it paused plans to build an mRNA manufacturing facility in Kenya to buy time to assess vaccine demand after being hit with $1 billion in losses and write-downs due to canceled orders.
-
Engineered T Cells Market Size, Growth, Trends and Forecast 2024-2033
4/11/2024
The global engineered T cells market size was estimated at USD 26.87 billion in 2023 and is projected to hit around USD 348.9 billion by 2032, growing at a CAGR of 32.96% from 2023 to 2032.
-
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033
4/3/2024
According to the latest research by Nova One Advisor, the global biotechnology market size was valued at USD 1.54 Trillion in 2023 and is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% from 2024 to 2033
-
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
3/20/2024
BioNTech SE reported financial results for the three months and full year ended December 31, 2023, and provided an update on its corporate progress.
-
BioNTech Announces Planned Retirement of Sean Marett
3/7/2024
BioNTech SE announced that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech.
-
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2/29/2024
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”) today reports fourth quarter and year end 2023 financial results and provides a corporate update.
-
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
2/8/2024
BioNTech SE and Autolus Therapeutics plc announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations.
-
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
1/30/2024
Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance(5) provided on December 13, 2023.
-
The antibody-drug conjugate market remains hot so far in 2024 with Tuesday’s collaboration and license agreement between Roche and MediLink Therapeutics to develop a next-generation ADC in oncology.
-
Pfizer Provides Full-Year 2024 Guidance
12/13/2023
Pfizer Inc. provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen transaction.
-
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
11/14/2023
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update.
-
After its deal with Tubulis in April 2023, Bristol Myers Squibb is continuing its antibody-drug conjugate buying spree by acquiring an asset from South Korea’s Orum Therapeutics.
-
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
11/6/2023
BioNTech SE reported financial results for the three and nine months ended September 30, 2023, and provided an update on its corporate progress.
-
Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications
11/6/2023
Biotheus Inc. ("Biotheus") today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.
-
Third-quarter revenues for antiviral treatment Paxlovid dropped 97% operationally compared with the prior-year period, while vaccine Comirnaty revenues declined 70% in the quarter.
-
Pfizer Reports Third-Quarter 2023 Results
10/31/2023
Pfizer Inc. reported financial results for the third quarter of 2023. The company reaffirms its 2023 revenue guidance range of $58.0 to $61.0 billion and its outlook for Adjusted diluted EPS of $1.45 to $1.65 provided on October 13, 2023.
-
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
10/26/2023
Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
-
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
10/24/2023
GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced an update on key strategic initiatives.